Cyclic GMP modulating drugs in cardiovascular diseases : mechanism-based network pharmacology
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology..
Mechanism-based therapy centred on the molecular understanding of disease-causing pathways in a given patient is still the exception rather than the rule in medicine, even in cardiology. However, recent successful drug developments centred around the second messenger cyclic guanosine-3'-5'-monophosphate (cGMP), which is regulating a number of cardiovascular disease modulating pathways, are about to provide novel targets for such a personalized cardiovascular therapy. Whether cGMP breakdown is inhibited or cGMP synthesis is stimulated via guanylyl cyclases or their upstream regulators in different cardiovascular disease phenotypes, the outcomes seem to be so far uniformly protective. Thus, a network of cGMP-modulating drugs has evolved that act in a mechanism-based, possibly causal manner in a number of cardiac conditions. What remains a challenge is the detection of cGMPopathy endotypes amongst cardiovascular disease phenotypes. Here, we review the growing clinical relevance of cGMP and provide a glimpse into the future on how drugs interfering with this pathway may change how we treat and diagnose cardiovascular diseases altogether.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Cardiovascular research - 118(2022), 9 vom: 20. Juli, Seite 2085-2102 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Petraina, Alexandra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.07.2022 Date Revised 24.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cvr/cvab240 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328161241 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328161241 | ||
| 003 | DE-627 | ||
| 005 | 20231225202348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cvr/cvab240 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM328161241 | ||
| 035 | |a (NLM)34270705 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Petraina, Alexandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cyclic GMP modulating drugs in cardiovascular diseases |b mechanism-based network pharmacology |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.07.2022 | ||
| 500 | |a Date Revised 24.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. | ||
| 520 | |a Mechanism-based therapy centred on the molecular understanding of disease-causing pathways in a given patient is still the exception rather than the rule in medicine, even in cardiology. However, recent successful drug developments centred around the second messenger cyclic guanosine-3'-5'-monophosphate (cGMP), which is regulating a number of cardiovascular disease modulating pathways, are about to provide novel targets for such a personalized cardiovascular therapy. Whether cGMP breakdown is inhibited or cGMP synthesis is stimulated via guanylyl cyclases or their upstream regulators in different cardiovascular disease phenotypes, the outcomes seem to be so far uniformly protective. Thus, a network of cGMP-modulating drugs has evolved that act in a mechanism-based, possibly causal manner in a number of cardiac conditions. What remains a challenge is the detection of cGMPopathy endotypes amongst cardiovascular disease phenotypes. Here, we review the growing clinical relevance of cGMP and provide a glimpse into the future on how drugs interfering with this pathway may change how we treat and diagnose cardiovascular diseases altogether | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cyclic GMP | |
| 650 | 4 | |a Guanylate cyclase | |
| 650 | 4 | |a Natriuretic peptides | |
| 650 | 4 | |a Nitric oxide | |
| 650 | 7 | |a Nitric Oxide |2 NLM | |
| 650 | 7 | |a 31C4KY9ESH |2 NLM | |
| 650 | 7 | |a Guanylate Cyclase |2 NLM | |
| 650 | 7 | |a EC 4.6.1.2 |2 NLM | |
| 650 | 7 | |a Cyclic GMP |2 NLM | |
| 650 | 7 | |a H2D2X058MU |2 NLM | |
| 700 | 1 | |a Nogales, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Krahn, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mucke, Hermann |e verfasserin |4 aut | |
| 700 | 1 | |a Lüscher, Thomas F |e verfasserin |4 aut | |
| 700 | 1 | |a Fischmeister, Rodolphe |e verfasserin |4 aut | |
| 700 | 1 | |a Kass, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Burnett, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Hobbs, Adrian J |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Harald H H W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular research |d 1967 |g 118(2022), 9 vom: 20. Juli, Seite 2085-2102 |w (DE-627)NLM000080209 |x 1755-3245 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2022 |g number:9 |g day:20 |g month:07 |g pages:2085-2102 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cvr/cvab240 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2022 |e 9 |b 20 |c 07 |h 2085-2102 | ||